Welcome to This Is MS!

     Modules
· Home
· Content
· Downloads
· Encyclopedia
· FAQ
· Feedback
· Forums
· Journal
· Private Messages
· Recommend Us
· Search
· Site_Map
· Stories Archive
· Submit News
· Surveys
· Top 10
· Topics
· Web Links
· Your Account

     Google
Google
Web
This is MS
These ads help pay for the upkeep of our site. They are automatically served by Google and are not affiliated with This is MS.

     Languages
Select Interface Language:


     Who''s Online
There are currently, 249 guest(s) and 82 member(s) that are online.

You are Anonymous user. You can register for free by clicking here

     Next Step

From the creators of This is MS comes Experience Project

EP is a community where members connect through shared life experiences-- like MS--and so much more. You are not defined by any one thing, so be your true self and find others just like you at Experience Project.

Get started by sharing your Multiple Sclerosis story.


     Donations

To remain unbiased, This is MS does not accept corporate sponsorships.

Therefore, we must rely on our users to help support us. Please donate to our upkeep if you have the means. Thank you!


 PRISMS Crossover Study Corroborates Benefit of Rebif as Treatment for RRMS

RebifThe PRISMS study, demonstrating the efficacy of Rebif, was completed in 2001. It demonstrated benefits in all outcome measures across the 2 year trial, particularly with respect to number of relapses, MRI activity and disability progression. As with all major trials, there was a placebo group, which provided the PRISMS study an interesting opportunity to investigate what would happen if the patients originally on placebo were then switched over to Rebif therapy. The results are consistent with what one might expect:

Beginning in the third year (after two years of placebo), the placebo patients were randomized into two groups, one receiving 22mcg, the other 44 mcg, subcutaneously 3 times per week. At the end of years 3 and 4, the patients were evaluated, and both groups showed a 54% reduction in mean relapse rate, as well as a "significant" improvement in disability progression, MRI activity and T2 lesion burden.

Again this is nothing surprising-- because the patient group was well understood in this study prior to inception of therapy, the results are slightly more striking (e.g., instead of comparing a patient to an average relapse rate expected of an RRMS''''er, you can compare the patient directly to their own relapse rate in the previous years).

The studies continue to corroborate that the Interferons do indeed work as disease modifying agents...

Click "read more" for the link to the abstract on PubMed...


Article Abstract Hosted at PubMed


Click here



 
     Login
Nickname

Password

Don't have an account yet? You can create one. As a registered user you have some advantages like theme manager, comments configuration and post comments with your name.

     Related Links
· More about Rebif
· News by Administrator


Most read story about Rebif:
Rebif Market Share Growing; Antegren Viewed as Biggest Threat


     Article Rating
Average Score: 0
Votes: 0

Please take a second and vote for this article:

Excellent
Very Good
Good
Regular
Bad


     Options

 Printer Friendly Printer Friendly






We encourage you to also visit our Multiple Sclerosis support community on Experience Project. Experience Project is a vast and powerful community where people connect anonymously through life experiences. It's made by the same people who built This is MS, on the premise that no single life experience-- like having MS-- defines a person. EP now covers over 5 million true stories about every possible life experience. Find and share yours!


Network Sites: Secret Confessions | Dream Meanings | Question and Answer | Song Meanings | Baby Name Meanings
Site Map

This site does not offer medical advice. All treatment decisions should always be made with the full consent of your physician.

 


All logos and trademarks in this site are property of their respective owners. The comments are property of their posters, quoted articles are © referenced source, all the rest © 2002-2010 by thisisMS.com.